In February 2026, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded its safety review of levamisole-containing medicines and recommended that their marketing authorisations be withdrawn from the EU market. EMA said the review found that the benefits no longer outweigh the risks for the treatment of parasitic worm infections because of the risk of leukoencephalopathy, described as a rare but serious side effect affecting the brain’s white matter.
EMA said the information reviewed showed that symptoms of leukoencephalopathy may occur after a single dose and may develop from within one day to several months after treatment. The agency also said the review did not identify any risk-minimization measures or patient subgroup in which the risk could be acceptably reduced. That is a striking outcome because it illustrates one of the most serious endpoints in pharmacovigilance: a review that does not end in wording updates or monitoring recommendations, but in a recommendation for market withdrawal.
For PV professionals, this is a valuable case study in how benefit-risk assessment works in practice. Safety reviews do not begin with the assumption that a product must be removed. They move through evidence, interpretation, and options. But where a serious risk is confirmed and no workable risk-reduction strategy is identified, regulators may conclude that continued authorization is no longer justified. That is exactly the logic EMA described in this case.
This decision also highlights the central role of PRAC within the EU pharmacovigilance system. EMA states that PRAC is responsible for assessing and monitoring the safety of human medicines, and that it publishes meeting highlights, agendas, and recommendations after its monthly meetings. The levamisole case shows why those outputs matter: they are not just procedural documents; they are points where major safety decisions become visible to the broader industry.
Another important lesson is that not all signals are equal. EMA notes on its PRAC safety-signal page that the presence of a signal does not itself prove a medicine caused the event. But signals are meant to trigger assessment, and sometimes those assessments lead to substantial regulatory action, including product information changes or broader decisions. Levamisole is an example of that continuum reaching one of its most consequential conclusions.
For sponsors and safety teams, cases like this reinforce the need for disciplined signal management, strong medical review, and thoughtful benefit-risk evaluation. They also remind the industry that pharmacovigilance outcomes can materially affect product availability, not just safety language. That is why public PRAC outputs deserve close attention.
Why this matters for PV professionals
The levamisole decision is a reminder that pharmacovigilance is not merely about collecting data. It is about following evidence to its regulatory consequences. Sometimes that consequence is a label update. Sometimes it is a market withdrawal.
0 Comments